UA41346C2 - Фармацевтична композиція, яка містить флуоксетин або його сіль, таблетка на її основі, спосіб виробництва таблетки, яка диспергується - Google Patents

Фармацевтична композиція, яка містить флуоксетин або його сіль, таблетка на її основі, спосіб виробництва таблетки, яка диспергується

Info

Publication number
UA41346C2
UA41346C2 UA95073401A UA95073401A UA41346C2 UA 41346 C2 UA41346 C2 UA 41346C2 UA 95073401 A UA95073401 A UA 95073401A UA 95073401 A UA95073401 A UA 95073401A UA 41346 C2 UA41346 C2 UA 41346C2
Authority
UA
Ukraine
Prior art keywords
fluoxetin
manufacture
pharmaceutical composition
salts
composition containing
Prior art date
Application number
UA95073401A
Other languages
English (en)
Russian (ru)
Inventor
МЕНДІСАБАЛЬ Флавіа АРХЕ
Мендисабаль Флавия Архе
Original Assignee
Ліллі С.А.
Лилли С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8286976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA41346(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ліллі С.А., Лилли С.А. filed Critical Ліллі С.А.
Publication of UA41346C2 publication Critical patent/UA41346C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Винахід відноситься до фармацевтичних засобів, що містять флуоксетину гідрохлорид та призначаються для приготування твердих фармацевтичних форм для перорального застосування. Запропонована фармацевтична композиція, що містить як активний інгредієнт флуоксетин або його сіль, одержану додаванням кислоти. Згаданий активний інгредієнт міститься в кількості від 4% до 7,5% (мас.) від загальної маси композиції. Завдяки наявності відповідних наповнювачів і коад'ювантів згадана композиція є прийнятною для виготовлення диспергованих таблеток прямим пресуванням.
UA95073401A 1994-07-20 1995-07-19 Фармацевтична композиція, яка містить флуоксетин або його сіль, таблетка на її основі, спосіб виробництва таблетки, яка диспергується UA41346C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09401593A ES2082723B1 (es) 1994-07-20 1994-07-20 Formulacion farmaceutica de fluoxetina en forma dispersable.

Publications (1)

Publication Number Publication Date
UA41346C2 true UA41346C2 (uk) 2001-09-17

Family

ID=8286976

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95073401A UA41346C2 (uk) 1994-07-20 1995-07-19 Фармацевтична композиція, яка містить флуоксетин або його сіль, таблетка на її основі, спосіб виробництва таблетки, яка диспергується

Country Status (30)

Country Link
US (1) US5747068A (uk)
EP (3) EP1072262A1 (uk)
JP (1) JPH0840884A (uk)
KR (1) KR100360130B1 (uk)
CN (2) CN1101187C (uk)
AT (1) ATE200733T1 (uk)
AU (2) AU692550B2 (uk)
BR (1) BR9503386A (uk)
CO (1) CO4410195A1 (uk)
CY (1) CY2241B1 (uk)
CZ (1) CZ287378B6 (uk)
DE (2) DE69520768T2 (uk)
DK (1) DK0693281T3 (uk)
ES (2) ES2082723B1 (uk)
FI (3) FI121262B (uk)
GR (2) GR960300064T1 (uk)
HU (1) HU228859B1 (uk)
IL (1) IL114641A (uk)
MY (1) MY114776A (uk)
NO (1) NO312225B2 (uk)
NZ (1) NZ272610A (uk)
PE (1) PE33996A1 (uk)
PL (1) PL181359B1 (uk)
PT (1) PT693281E (uk)
RU (1) RU2145850C1 (uk)
SI (1) SI0693281T1 (uk)
TR (1) TR199500878A2 (uk)
TW (1) TW404840B (uk)
UA (1) UA41346C2 (uk)
ZA (1) ZA956074B (uk)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT869772E (pt) * 1995-12-27 2002-03-28 Janssen Pharmaceutica Nv Forma galenica solida bioadesiva
JP3180350B2 (ja) * 1996-02-29 2001-06-25 藤沢薬品工業株式会社 β―ラクタム系抗生物質含有錠剤およびその製造法
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
ATE238774T1 (de) * 1997-10-09 2003-05-15 Dexcel Pharma Technologies Ltd Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
JP4504467B2 (ja) * 1998-07-30 2010-07-14 佐藤製薬株式会社 口腔内崩壊性錠剤
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
RU2174391C1 (ru) * 2000-10-24 2001-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с антидепрессантной активностью
UA75135C2 (en) * 2001-05-01 2006-03-15 Pfizer Prod Inc Dry granulation method for manufacturing pharmaceutical composition containing tetrahydronaphthalene-2-ol derivative and low dosage tablet compositions
CZ20033116A3 (cs) * 2001-05-15 2004-09-15 Warner-Lambert Company Llc Způsob výroby lékové formy fenytoinu sodného užívající kompaktor
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
DE10351448A1 (de) 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
NZ564167A (en) * 2005-05-17 2009-12-24 Actelion Pharmaceuticals Ltd Dispersible tablet comprising 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-benzenesulfonamide (bosutan)
TWI383809B (zh) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
CN100353943C (zh) * 2005-07-04 2007-12-12 广州固志医药科技有限公司 乳酸氟罗沙星分散片及其制备方法
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20070043097A1 (en) * 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
FR2891147B1 (fr) * 2005-09-28 2007-12-07 Ethypharm Sa Comprimes orodispersibles de principes actifs amers
EP1993377B1 (en) * 2006-03-03 2012-01-04 Symrise AG Pressed agglomerates suitable for consumption having retarded aroma release
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
FR2910319B1 (fr) 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
CN101677945A (zh) * 2007-05-08 2010-03-24 赫尔克里士公司 坚固的快速崩解片剂制剂
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
KR101438629B1 (ko) 2013-02-04 2014-09-05 현대자동차 주식회사 체결 장치 및 그 제어 방법
BR112016013164B1 (pt) 2013-12-27 2022-07-26 Chugai Seiyaku Kabushiki Kaisha Preparações sólidas contendo tofoglifozina e processos para produzir a mesma
RU2690685C2 (ru) * 2014-10-03 2019-06-05 Новартис Аг Фармацевтические композиции, содержащие алпелисиб
CN107334742B (zh) * 2017-08-18 2020-01-31 山东力诺制药有限公司 一种盐酸氟西汀分散片及其制备方法
KR102453105B1 (ko) * 2020-10-26 2022-10-07 현대제철 주식회사 침지노즐 크리닝 장치
CN114699374B (zh) * 2022-04-01 2024-02-20 佛山市南海东方澳龙制药有限公司 一种猫犬专用盐酸氟西汀固体制剂及其制备和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034911A (en) * 1959-03-25 1962-05-15 Nat Starch Chem Corp Tablet disintegrants
US3091574A (en) * 1961-09-05 1963-05-28 Bristol Myers Co Tablet disintegrants
DE1228029C2 (de) * 1964-05-09 1973-05-17 Merck Ag E Verfahren zur Herstellung von Tabletten durch Pressen von Pulvergemischen ohne vorhergehende Granulation
NL159577B (nl) * 1968-02-15 1979-03-15 Organon Nv Werkwijze ter bereiding van snel desintegrerende vaste vormstukken.
US3622677A (en) * 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1498857A (en) * 1975-07-03 1978-01-25 Leo Ab Antidepressant composition
JPS6056659A (ja) * 1983-09-08 1985-04-02 Yanmar Diesel Engine Co Ltd 農用トラクタ−のブレ−キ装置
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4844908A (en) * 1986-11-27 1989-07-04 Duphar International Research B.V. Method of preparing tablets with clovoxamine fumarate and tablets thus prepared
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
GB8921069D0 (en) * 1989-09-18 1989-11-01 Wellcome Found Pharmaceutically active compound,preparation and use
EP0449562A3 (en) * 1990-03-29 1992-03-18 Eli Lilly And Company Use of r-fluoxetine as selective serotonin ic-receptor ligands
CA2039102A1 (en) * 1990-03-29 1991-09-30 David W. Robertson Compounds affecting serotonin receptors
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
AU1373692A (en) * 1991-11-15 1993-06-15 Sepracor, Inc. Methods and compositions utilizing pure s(+) isomer fluoxetine
JPH0656659A (ja) * 1992-06-10 1994-03-01 Natl Sci Council 直接打錠できる薬学組成物及びその錠剤の製造法

Also Published As

Publication number Publication date
AU8317498A (en) 1998-11-05
CN1440745B (zh) 2012-03-21
ES2082723B1 (es) 1996-10-01
NO312225B1 (no) 2002-04-15
DK0693281T3 (da) 2001-05-21
CO4410195A1 (es) 1997-01-09
BR9503386A (pt) 1996-02-27
ZA956074B (en) 1996-05-14
IL114641A0 (en) 1995-11-27
NO952863D0 (no) 1995-07-19
NO952863L (no) 1996-01-22
GR960300064T1 (en) 1996-11-30
KR100360130B1 (ko) 2003-01-29
FI20011851A7 (fi) 2001-09-20
FI20011852L (fi) 2001-09-20
NO312225B2 (no) 2002-04-15
TW404840B (en) 2000-09-11
HU9502154D0 (en) 1995-09-28
HUT75036A (en) 1997-03-28
TR199500878A2 (tr) 1996-06-21
EP1072262A1 (en) 2001-01-31
ES2082723A1 (es) 1996-03-16
FI953515A0 (fi) 1995-07-20
CZ188095A3 (en) 1996-02-14
CN1101187C (zh) 2003-02-12
IL114641A (en) 1999-04-11
PE33996A1 (es) 1996-09-09
CN1123142A (zh) 1996-05-29
NZ272610A (en) 1997-08-22
CZ287378B6 (en) 2000-11-15
AU692550B2 (en) 1998-06-11
CY2241B1 (en) 2003-07-04
RU2145850C1 (ru) 2000-02-27
AU707210B2 (en) 1999-07-08
ATE200733T1 (de) 2001-05-15
ES2091737T1 (es) 1996-11-16
SI0693281T1 (en) 2001-12-31
US5747068A (en) 1998-05-05
PT693281E (pt) 2001-08-30
DE69520768D1 (de) 2001-05-31
PL309721A1 (en) 1996-01-22
FI121262B (fi) 2010-09-15
FI20011851L (fi) 2001-09-20
CN1440745A (zh) 2003-09-10
EP0693281A2 (en) 1996-01-24
DE69520768T2 (de) 2001-08-23
KR960003720A (ko) 1996-02-23
AU2509895A (en) 1996-02-01
EP1070501A1 (en) 2001-01-24
JPH0840884A (ja) 1996-02-13
GR3035788T3 (en) 2001-07-31
HK1012573A1 (en) 1999-08-06
EP0693281A3 (en) 1996-10-30
FI953515L (fi) 1996-01-21
PL181359B1 (pl) 2001-07-31
HU228859B1 (en) 2013-06-28
MY114776A (en) 2003-01-31
DE693281T1 (de) 1997-04-03
FI20011852A7 (fi) 2001-09-20
EP0693281B1 (en) 2001-04-25
ES2091737T3 (es) 2001-06-01

Similar Documents

Publication Publication Date Title
UA41346C2 (uk) Фармацевтична композиція, яка містить флуоксетин або його сіль, таблетка на її основі, спосіб виробництва таблетки, яка диспергується
EP1685839B8 (en) Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
ATE206304T1 (de) Bioadhesive feste arzneimittelform
ATE260646T1 (de) Schnell zerfallende orale dosierungsform
ATE252899T1 (de) Schilddrüsenhormone enthaltende mittel
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
HUP0003897A2 (hu) Pezsgő sav-bázis párt tartalmazó gyógyászati kompozíciók
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
ATE158504T1 (de) Brausemischungen enthaltend ibuprofen und verfahren
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
UA85359C2 (uk) Таблетка, що містить гранульований матеріал з kmd-3213
SE9901573D0 (sv) New compounds
EA200301040A1 (ru) Способ производства фармацевтической композиции низкой дозы
RU2002123182A (ru) Содержащая ибупрофен композиция
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
BRPI0407438A (pt) Sistema terapêutico compreendendo amoxicilina e ácido clavulânico
OA07029A (fr) Le chlorure de gallium, nouveau médicament anti-cancéreux.
SE9901572D0 (sv) New compounds
BG94934A (bg) Твърди лекарствени форми за орално приложение,съдържащи ифосфамид като активно вещество
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
PT1121109E (pt) Formulacao bifasica contendo tramadol
RU94032792A (ru) Применение 5нтiа - антагонистов для прекращения использования табака
ATE288756T1 (de) Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
EA200101157A1 (ru) 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ